Outlook Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 3. Defaults Upon Senior Securities
None. However, as described in Note 7 to the unaudited interim consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, on December 31, 2025, the Company did not satisfy the required $3,000,000 Quarterly Debt Reduction Obligation under the March 2025 Note, which constituted a “Major Trigger Event” (as defined in the March 2025 Note) and resulted in (i) an automatic 10% increase to the outstanding balance and (ii) an adjustment to the Conversion Price. Subsequent to December 31, 2025, Avondale converted $6,910,000 of principal and accrued interest into 15,057,649 shares of common stock, satisfying the Quarterly Debt Reduction Obligation for both the quarters
ended December 31, 2025 and March 31, 2026. Avondale has confirmed that this Major Trigger Event has not resulted in an Event of Default (as defined in the March 2025 Note).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.